100
Participants
Start Date
October 28, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
September 30, 2026
SMOFlipid® (lipid injectable emulsion)
"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
RECRUITING
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
NOT_YET_RECRUITING
Emory University Hospital, Atlanta
RECRUITING
Riley Hospital for Children, Indianapolis
NOT_YET_RECRUITING
The University of Chicago, Chicago
Lead Sponsor
Fresenius Kabi
INDUSTRY